These compounds may accordingly be useful for the differential diagnosis of neurological conditions in elderly subjects on the basis of the Sunitinib cost distribution of tau lesions, thereby opening up novel avenues for research in elucidating mechanisms of tau-mediated neurodegeneration, as well as tau-focused biomarkers and therapies. Despite numerous efforts to develop imaging ligands to visualize tau pathologies in the brains of patients with AD and related tauopathies, the urgent need for these tau biomarkers remains largely unmet. To address

this significant challenge, we also took advantage of a multimodal imaging system, which facilitates a quick and label-free validation of candidate compounds in terms of

their transfer to the brain and retention in tau-rich regions. In addition, subcellular-resolution imaging optics exemplified by two-photon laser scanning microscopy provided proof of the rapid transfer of intravenously administered potential tau pathology imaging agents from plasma to the CNS extracellular matrix and subsequently to the cytoplasm of neurons, where they can bind to intracellular tau inclusions. Based on these encouraging preliminary data using nonlabeled compounds, a subset of these compounds was radiolabeled for use in PET imaging of Tg mice that model tau pathology, and a radioligand that yielded the best visualization of tau lesions in these Tg mice was selected for further testing in human AD patients and NC subjects as well as patients check details with

probable CBD. This stepwise strategy enabled us to identify and advance the most promising PET probe for the visualization and quantitative assessment of tau pathology in the CNS of living human subjects. Interestingly, another research group has recently reported development of 18F-labeled PET ligands for tau lesions mostly through assessments of binding to brain tissues, but not recombinant tau assemblies (Zhang et al., 2012 and Chien et al., 2013), as in the present approach. These radioligands have been implied to produce considerably high contrasts for tau pathologies in living AD brains, Oxalosuccinic acid and relatively long radioactive half-life of 18F would enable delivery of radioligands from a radiosynthesis sites to multiple PET facilities. [11C]PBB3 has distinct advantages over these compounds, as exemplified by affinity for diverse tau lesions, including Tg mouse tau aggregates, applicability to multimodal imaging, and induction of smaller radioactive exposure than 18F-labeled ligands. In the present work, we clinically validated the performance of [11C]PBB3 as a tau imaging agent by comparing the distribution of [11C]PBB3 with that of [11C]PIB in AD brains.